Cytrellis Biosystems

CompanyUnited States

Cytrellis Biosystems develops one asset, in human trials (ellacor in gene expression). Mostly device; based in the United States.

1
Asset
Furthest stage
Human trials
0
Trials
0
Signals

Pipeline

1
  • ellacor

    Micro-coring technology that removes micro-columns of skin to reduce skin laxity and wrinkles

    Human trials, Device, gene expression, glp1 agonist

Full company profiles: pipeline, trials, funding and people.

See Pro

Intelligence